CNBC February 13, 2025
Key Points
– U.S. investors like Bain Capital Life Sciences and large pharmaceutical companies like Merck are increasingly looking for new medicines in China.
– Almost 30% of Big Pharma deals with at least $50 million up front came from China last year, up from 20% the year before and 0% only five years before, according to data from DealForma.
– The increase in China deals comes as President Donald Trump and U.S. policymakers pursue protectionist policies in technology like artificial intelligence and semiconductors.
A little-known biotech company stunned the biopharmaceutical industry last spring when it declared an “unprecedented” achievement: its experimental cancer drug looked more effective than Merck‘s Keytruda in a clinical trial. The company, Summit Therapeutics, licensed the...
Today's Sponsors
Today's Sponsor